인사이트
Insights From Our Experts
Articles
Succeed When Others Fail: Avoiding 20% in Investment Waste During Launch
It’s a long-standing perception that pharma overspends during launch, but we did not have the data or methodology to understand or validate this notion. Until now. New Research by the Numbers 10: Recent analysis across 10…
THINK BEYOND THE THERAPY: Demystifying the Complexities of Cell and Gene Therapy Commercialization
While much attention has been given to the novel science behind cell and gene therapies, ultimately the success of every precision medicine starts and ends with the patient. Whether coordinating a cell or gene therapy clinical…
Importance of Impactful Medical Information Content
Medical Information (MI) services have evolved as technology has advanced and healthcare professionals’ and patients’ needs and preferences have changed. Understanding the audience, identifying the most beneficial content format, and utilizing the preferred channels of communication…
WEBINAR: Innovative Pharmacy and Distribution Models Driven by Market Dynamics, Product Type, Site of Care and Reimbursement
The landscape of the pharmaceutical distribution industry is shifting from a familiar state to a novel market calling for a new level of channel service due to forces of innovation. In this webinar, EVERSANA’s Scot Buchanan,…
How to Ensure Speed and Efficiency When Launching in Europe
Today is an extraordinary time for medical innovation. The pharmaceutical industry is yielding protection against diseases, focusing more on rare and complex disease treatments, and the world is getting better health outcomes. Global life expectancy is…
Reversing the Complexity of Oncology Commercialization: How to solve for launch challenges in a chaotic ecosystem
As physicians, patients and caregivers tirelessly fight complex diseases, a growing number of drug manufacturers are preparing to launch new oncology therapies. These high-science therapies are entering the market at rapid rates: Presently, there are 500…
A Holistic Launch in Europe Is Possible, But Change Is Necessary
Unless you live in Europe or have commercialized a product in this region, you may not realize that the European pharmaceutical market is a huge contributor to global health, and it is currently undergoing market-wide changes.…
How to Eliminate Access, Affordability and Adherence Barriers in 2022
Today, everyone expects both digital and human outreach, and manufacturers face the challenge of trying to strike the right balance between tech and in-person touchpoints to enhance patient and healthcare provider (HCP) engagement. Despite all the…
A Partnership Q&A with EVERSANA and Shorla Pharma
As industry and patient needs progress beyond traditional commercialization models, new models are needed to deliver products to patients quicker, especially when launching in international markets. Still asking yourself how to execute on a global pharmaceutical product launch? EVERSANA has the answer to this question and others that you’ll have…
QUIZ: How Mature Are Your HCP & Patient Engagement Strategies?
In the increasingly virtual world we live in, there’s no denying the instrumental role that technology plays in engaging patients and healthcare providers (HCPs). With heavier reliance across industries on text alerts, automated phone reminders and…